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SYNOPSIS OF THESIS 
A NOVEL PROTEIN FROM Mycobacferium bovis BCG : 
BIOCHEMICAL AND IMMUNOLOGICAL STUDIES 
A] INTRODUCTION 
Tuberculosis (TB), caused by bac~lli Mycobacterzum tuberculoszs (MTB), remains 
one of the most mtncate world health problems It mfects 6-8 mlll~on people worldw~de 
annually and causes 2-3 mdlion deaths every year causmg the largest number of deaths 
by any smgle ~nfect~ous agent m a year ' In 1994, of the 14 milllon people infected mth 
AIDS worldwide, 5 6 mill~on people were coinfected w ~ t h  TB 113rd of the world's 
population 1s mfected with TB bad11 and 50% of these cany multidrug-resistant strains 
Indla has nearly 1/3rd of world's TB pat~ents It 1s estimated that TB wlll h l l  30 milhon 
people this decade and considermg the potential danger of a global ep~dem~c, WHO 
declared a global emergency against TB in 1993 India 1s estimated to have nearly one- 
third of the world's TB patrents Among the AIDS pat~ents In Indla, the most prevalent 
cause of death is due to TB rnfection 
Mycobacter~a infect through droplet nuclei conta~ning 2-3 bacilll and on infect~on 
res~de In host macrophages The~r intracellular location, lipid-nch cell wall and 
protective capsule inh~bit he attack by ant~bodies and complement and also protect ~t 
aga~nst bacter~cldal act~on of macrophages Although ant~bod~es are produced during 
infect~on, ~t 1s the cell-medlated irnrnune system, wh~ch plays a predominant role In 
mycobacterial ~mmun~ ty  
There are many reasons why the mycobactenal diseases remain a problem nearly 
50 years after the introduction of BCG vaccme and many effectwe chemotherapeutlc 
agents The major reasons being incons~stency of BCG vaccine's efficacy and lengthy 
treatment regimens Improper treatment of TB for long duration gives an opportunity for 
MTB to emerge as drug-resistant strains A greater understanding of the mechanism of 
mycobactenal pathogenes~s and immunity w ~ l l  certa~nly be requred in order that more 
effectlve vaccmatlon and treatment programmes be developed 
To contain the TB mfect~on, BCG vacc~nat~on has been trled for the past 50 yrs 
but is cons~dered not to be very effectlve from the tnals conducted in south Indla in 1980s 
and its efficacy is found to be only about 50% Hence to develop an effectwe vaccine, 
specrfic antigens of mycobactena are belng identified w ~ t h  respect to their ab~lity to 
generate an effectlve and long lastlng immune response - both cellular and humoral 
Individual antigens are bemg isolated, punfied and character~sed m this respect This has 
the potentlal pract~cal benefits of ~dentify~ng cand~date molecules for use as Subun~t 
Vaccines and as reagents for Imrnunodlagnostic Tests Much research is being done to 
identlfy indwidual protem fractions for use as improved diagnostic reagents to achieve 
this goal A candidate vaccine agalnst TB should be able to generate good cellular as well 
as humoral immune responses m the host 
Bj AIM AND OBJECTIVES 
The aim of our study is to ident~fy new protein(s) of the vaccme stram 
Mycobacterrurn bovls BCG (BCG), pur~fy and characterise lt w ~ t h  respect to the mrnune 
response generated in exper~mental anlmals Slnce BCG is used as a vaccme for TB, 
determirung spec~fic antigens of BCG, which are imrnunogenlc zn vzvo, may allow its use 
to Improve the efficacy of ex~sting vaccine 
C] EXPERIMENTS AND RESULTS 
11 IDENTIFICATION 
Towards t h ~ s  goal we have used 14 random clones from the genomic cosmid 
DNA llbrary of Mycobacterzum bovls BCG (Pasteur stram) for our study 
The genomic library was made by Jacobs et a1 by partial Sau3AI digestion of 
BCG genomlc DNA to generate fragments of size approx 30-40Kbp The Sau3AI drgest 
was run on a 0 8% agarose gel and fragments of size 30-40Kbp were eluted out Thls was 
cloned in a cosm~d expression vector pYUB 18 and the clones were electroporated into a 
fast-growing mycobactenal strain Mycobacterzum smegrnatzs The clones obtalned were 
screened for production of BCG-specific protems by screemng the cell son~cates of 
clones with anti-BCG sera Fourteen clones from these were randomly picked for our 
study 
These clones were nos. 1, 3, 17, 25, 110, 119, 147, 154, 156, 223, 236, 277, 325 
and 331 Clone Vector (V) contamng pYUB 18 vector DNA, but no BCG insert DNA, in 
Msmegmatzs (smegmatis) was used as control for comparatrve studies These clones 
were further screened for product~on of BCG-spec~fic protems by western 
~mmunoblott~ng usmg absorbed and unabsorbed anti-BCG sera (An Absorbed serum 
implies that anti-BCG sera were reacted wlth host smegmatis cell son~cate-lyoph~hsate to 
ehmmate ant~bodies m the sera that crossreact with host smegmatls proteins After 
absorpt~on the sera were centrifuged at 15k, 20', 4OC and the supernatant contaimng 
antibod~es specific to BCG proteins, was isolated Unabsorbed sera IS not absorbed w~ th  
host cell sorucate proteins ) 
T h s  screemng identified e~ght clones, of the fourteen, wh~ch produced distinct 
BCG protems ranging in slze from 15 to 97 kDa These were clones 17, 25, 119, 147, 
223,236,277 &331. 
Further we wanted to determine rf these BCG-spec~fic proteins are recogn~sed by 
TB patlent sera The recognitron of BCG protems by TB patient sera will not only 
ind~cate that there is a predominant immune response agamst same protems in MTB but 
also show that they can be used as potential candidates for use as subunlt vacclne or be 
used to improve the efficacy of existlng BCG vaccine aga~nst TB 
Cell son~cate of the above 8 clones were then screened using TB patient sera 
Protein samples were run on 1 O%SDS-PAGE gel and ~mrnunostained usmg absorbed and 
unabsorbed (as described earlier) TB patient sera Proteins produced by clones 17, 119 
and 236 were recogn~sed by the patient sera 
Secreted proteins of mycobacterium are among the first ant~gens against which 
the host mmune system mounts an irnmune response Hence we wanted to determine if 
the clones secrete any of the expressed proteins The eight clones' culture supernatants 
were isolated and protein precipitated by acetone-precipitation Absorbed and unabsorbed 
anti-BCG sera as well as TB patient sera were used to screen the supernatant proteins 
Only clones 147 and 154 produced secreted BCG protems of approx 28 kDa 
Of these clones which were screened, clone 236 produces a 56kDa protein, which 
is a BCG-specific protein and is also recogmsed by TB patient sera This 56 kDa protein 
was identified for further study that includes ~ t s  pur~fication, characterisation and 
immunological studies 
21 CHARACTERISATION 
Polyclonal antibodies were ralsed against the 56kDa protein In rabbits The clone 
236 son~cate was run on 10%SDS-PAGE gel and stained wlth coomassie blue The 
protein band of interest was cut out of the gel and electroeluted 300ug of this eluted 
protein was emulsified with Freund's Incomplete Adjuvant (FIA) and injected 
lntradermally on the back in rabbit at multiple locations Four weeks later a booster dose 
of 3OOug of the electroeluted protein was again lnjected intradermally in same rabbit One 
week later the rabbit was bled through the ear vem and 25ml blood collected from it 
Serum was Isolated and using ProteinA-agarose affinity column punfied anti-56kDa 
protein antibodies An indirect-ELISA, for anti-56kDa protein antibodies in the tsolated 
serum, gave a titre of 1 64,000. 
To determine if t h ~ s  56kDa protein is one of the already known mycobacterial 
proteins, we screened the clone236 cell sonicate with a range of monoclonal antibodies 
against known proteins of mycobacteria None of the twelve monoclonals used ~dentified 
our protein of interest The heat-shock proteins (HSPs) of mycobacteria have a theoretical 
molecular weight of 56kDa, same as our protein of interest Clone 236 was gwen heat- 
shock at 42OC for a few hours, to find ~f the 56kDa protein is a heat-shock protem The 
monoclonals agalnst the heat-shock proteins of mycobactena did not ident~fy the 56kDa 
protein ind~cating that it's not a heat-shock protein Moreover western immunoblottmg, 
usug absorbed anti-56 ant~body, of heat-shocked clone 236 sonlcate d ~ d  not show an 
increase in amounts of 56kDa protem in response to the heat shock, which is expected of 
the HSPs 
BCG and MTB have a homology of >95% at the DNA level and hence most 
protems w l l  be common in both these mycobactena Hence the presence of 56kDa 
protem was determined in Mycobacterzum tuberculosis H37Ra strain Western 
tmrnunoblott~ng of clone 236 and MTB somcates, using absorbed anti-56 sera, md~cates 
that t h s  protein is present In MTB also and even in case of heat-shocked MTB the levels 
of t h ~ s  protein are not increased, confirming our earher finding that its not a HSP 
The presence of this 56kDa protein in ten different specles of environmental 
mycobacteria was deterrnlned These 10 mycobacterlal specles along wlth MTB-H37Ra 
and clone 236 were grown and cell sonicates were made These were western 
imrnunoblotted using absorbed anti-56 antibody The 56M)a protem is identified only In 
MTB and clone 236 sonlcates but not In any other species of environmental mycobacteria 
studled 
To determine the identity of 56kDa protem, it was punfied by electroelution from 
10% SDS-PAGE gel The purity was checked again by runrung on 10% SDS-PAGE 
followed by silver staining and ~t was found to be a single band This was used for N- 
terminal amino acld sequencing and also for internal sequencing The purified protein 
was westem-transferred to PVDF membrane for N-terminal sequencing For internal 
amino ac~d  sequencing, it was run on a 10% SDS-PAGE and stamed w ~ t h  Coomassie 
Blue G-250 and destained In-gel Tryptic digest~on of the protem was carried out and one 
peptide of the d~gest, purlfied by HPLC, was sequenced to give the internal ammo ac~d  
sequence 
The N-terminal amino ac~d  sequence was found to be - 
TGNLVTKNSLTPDVRNGID 
The mternal arnino acid sequence was found to be - 
LYQFAAAGDLAFPAINVNDSV 
An online BLAST search for homology to these peptide sequences revealed 100% 
homology with a gene from the MtubercuIosrs genome sequence database This gene 
codes for an enzyme- S-Adenosyl-L-Homocysteine Hydrolase (SAHH) also called as 
Homocysteinase Ths  enzyme has not been purified and reported fiom Mycobacteria but 
has been studied well in humans and other prokaryotes The sequence of t h s  newly 
identified protem has been submitted to SWISS-PROT protein database (Accession No.- 
P81858) 
SAHH catalyses the reversible hydrolysis of S-adenosyl-L-homocysteine to 
Homocysteine and Adenosine In vzvo the reaction is favoured In the hydrolytic direction 
because of the rapid metabolism of homocysteine and adenosine But In vrtro the 
synthetic reaction 1s favoured 
The theoretical mol wt of t h ~ s  protein is 54323 6 Dalton and pI 1s 5 07 The 
mol wt as determined fiom 10% SDS-PAGE gel when compared wth  known mol wt 
standards is approx 56,000 Dalton and the pI determined from Isoelectric focussing gel 
is approx 5 0 
To determine if the SAHH protem is glycosylated, the electroeluted protein was 
run on a 10% SDS-PAGE along w t h  clone 236 sonicate and western imrnunoblotted 
onto rutrocellulose ConA lectin Western blottlng for glycoprotein detect~on was done 
wh~ch identified the 56kDa protein, indicating that it's a glycoproteln 
Cyanogen brom~de cleavage of SAHH protein generates 7 detectable peptide 
fragments on a 10% Tns-Tncine gel, which when assayed by ConA lectin western 
blotting ~dentifies one glycopeptide fiom all the fragments generated. This accounts for 
the glycosylation of the SAHH protein 
Two-dimensional electrophoresis (2-DE) of electroeluted SAHH protein was done 
by O'Farrell's method The s~lver-stamed profile of t h s  protein showed 3-4 closely 
spaced spots, wh~ch are all, ident~fied, when western imrnunoblotting is done using 
absorbed anti-56 sera The mult~ple spots are as a result of microheterogeneity that's 
present ~n this protein T h ~ s  1s also consistent with other such reports for this protein in 
other microorganisms and hgher eukaryotes 
31 PURIFICATION 
An attempt was made to pur~fy the SAHH proteln by conventional methods and 
was successful m part~ally pur~fy~ng the protein Clone 236 sonicate was gwen 
d~fferential ammonium sulphate fract~onat~on f 0-40% followed by 40-60% The SAHH 
protein appeared prominently in 40-60% fract~on though it was also present in 0-40% 
fraction But the amounts of other protem contam~nants were much reduced in the 40-60 
% fiact~on T h ~ s  fiact~on was then loaded on a DEAE-Sephacel ion-exchange column and 
eluted first w ~ t h  lOmM Tr~s-C1, pH-7 4 contalnmg 0 2M KC1 and 0 5mM Dlth~othreitol 
(DTT) followed by lOmM Tns-Cl conta~ning 0 5M KC1 and 0 5mM DTT The SAHH 
proteln was eluted in the 0 5 M KC1 fract~on and m a y  contamrnatmg proteins were 
eliminated in t h ~ s  tep T h s  fraction was then loaded onto Sephadex G200 gel filtration 
column and eluted with lOmM Tns-C1 containing 0 5mM DTT and 0 5mM EDTA The 
SAHH protein eluted In the void volume fract~on lndicat~ng that ~t might be assoc~ated 
into a mult~meric actwe protein m the cells T h ~ s  IS also the case In other prokaryotes and 
eukaryotes studled In this step also most low mol wt contarninatmg protelns were 
removed In all these steps the SAHH prote~n was highly enriched as seen from its 
amounts when these samples are run on 10% SDS-PAGE gel and s~lver-stamed 
J] IMMUNOLOGICAL STUDIES 
The immune response of experimental animals to SAHH protein was detemmed 
6-12wks old C57BLl6, male mice were used for these expts Spleenocyte proliferative 
response to SAHH protem was determmed by uslng varying concentrat~ons of protein 
In~t~ally the spleenocyte response to unprimed spleenocytes was determmed In mice, 
wh~ch had not been Injected with SAHH prote~n To study the primary response 4 
experimental and 2 control mlce were used The expt a1 mice were Injected with lOug 
each of electroeluted SAHH prote~n emulsified m FIA, while the control mice were not 
mjected w ~ t h  antigen One week after mjection the mlce were bled to collect serum for 
deterinmatlon of antibody response before sacnfic~ng them to isolate spleenocytes The 
spleen cells from expt a1 and control mlce were pooled separately and used for the assay 
106cells/we11/200ul were used In the assay The ant~gen was added to the samples and 
~ncubated ~n 37OC, humiddied C02 incubator for 72 hrs 20ul/well (=luCi) of 1 20 
d h t e d  tntiated-thymidine was added and incubated for a further 24 hrs Cells were then 
harvested and 3~-counts  were taken 
Sim~larly the secondary response to SAHH protem In mrce was determined Two 
weeks after first injection, a booster dose of lOug each SAHH proteln In FIA was given 
to the set of expt a1 an~mals The control mlce were not lnjected One week after the 
booster Inject~on the mlce were first bled to isolate serum and then sacnficed to  sola ate 
spleenocytes Spleenocyte proliferation assay was set-up for 72 hrs as m the case of 
prlmary response The results of these expts suggest that the SAHH proteln is 
lmmunogenlc m expt a1 mice w ~ t h  a prohferation Index over the control samples of 2 2  
The antibody response in these mlce to SAHH protein also Indicated that it 1s 
mmunogenic in generating antibody responses also The secondary response to this 
protein 1s many folds as compared to the primary response as detected by ~nd~rec t  ELISA 
usmg the sera from expt a1 and control animals 
In our earlier expts also we have shown that the SAHH protein is recognised by 
TB patlent sera, whch ind~cates that rt generates antibody responses in TB patlents also 
D] SUMMARY AND DISCUSSION 
From the genomic, cosmid expression library of Mbovzs BCG In Msmegmatzs 
we have identified a clone 236 which produces a novel protein of M bovzs BCG We 
have further attempted to purify and characterise this protein 
The N-terminal and internal amino acid sequencing of the gel-purified protein 
reveals that it's a new protein from Mycobacteria that has not been prevrously reported 
This protein IS an enzyme called S-adenosyl-L-homocysteine hydrolase whch catalyses 
the revers~ble hydrolysis of S-adenosyl-L-homocysteine to homocysteine and adenosine 
The Mol wt and pI of this protern has been found to be approx 56kDa and 5 0 
respectively The protein is also a glycoprotein and IS not secreted by the cells Its 
location is cytoplasmic The protein, on cyanogen bromide cleavage, generates 7 
detectable peptide fragments, one of which is a glycopeptide 2-DE of the protein 
indicates that there's Inherent microheterogeneity in the protein e~ther due to different 
subunits of the enzyme or due of different post-translational modifications of it l k s  
might be giving rise to the multiple spots on the 2-DE gels In other species of 
microorganisms, t h ~ s  proteln occurs either in some cases as a dimer or in most other cases 
as a tetrarner Also in some cases its reported to have two different subunlts that have 
similar mol wt 
The protern is also present m MTB-H37Ra stram but 1s not present in ten other 
species of environmental mycobacteria that we studled As th~s  protein is a vital enzyme 
for both prokaryotes and eukaryotes, it might be present in other species of mycobacteria 
but might have a d~fferent Mol wt than the one in BCG and MTB Hence rt 1s not 
~dentified, by the absorbed antibod~es to this protem, in other species 
Partial purification of the protein has been done by conventional methods using 
ammonium sulphate fractionation, DEAE-Sephacel ion-exchange chromatography and 
Sephadex G200 gel filtration 
Immunological studres in C57BL/6 mice reveal that the protein can generate 
cellular as well as humoral responses Also it has been found to generate hurnoral 
responses m TB patients This indicates that lt may play a role m the immune response to 
mycobactena in the mfected hosts 
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